(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one

C122H121F4N23O12 — CID 159309082

IUPAC(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one
SMILESCC(C)Oc1cccc(NC(=O)c2cccc3c2O[C@H](C)CC(=O)N3)c1.C[C@@H]1CC(=O)Nc2cc(C(F)(F)F)cc(-c3ccc4c(c3)c(C3CC3)nn4C)c2N1.C[C@@H]1CC(=O)Nc2cc(F)cc(-c3ccc4c(c3)c(C3CC3)nn4C)c2N1.C[C@@H]1CC(=O)Nc2cccc(-c3cccc(-c4nn[nH]n4)c3)c2N1.C[C@@H]1CC(=O)Nc2cccc(C(=O)Nc3cccc(-c4cnco4)c3)c2O1.Cc1ccc(-c2ccc3c(c2)c(C2CC2)nn3C)c2c1NC(=O)C[C@@H](C)N2
InChIInChI=1S/C22H21F3N4O.C22H24N4O.C21H21FN4O.C20H17N3O4.C20H22N2O4.C17H16N6O/c1-11-7-19(30)27-17-10-14(22(23,24)25)9-15(21(17)26-11)13-5-6-18-16(8-13)20(12-3-4-12)28-29(18)2;1-12-4-8-16(22-20(12)24-19(27)10-13(2)23-22)15-7-9-18-17(11-15)21(14-5-6-14)25-26(18)3;1-11-7-19(27)24-17-10-14(22)9-15(21(17)23-11)13-5-6-18-16(8-13)20(12-3-4-12)25-26(18)2;1-12-8-18(24)23-16-7-3-6-15(19(16)27-12)20(25)22-14-5-2-4-13(9-14)17-10-21-11-26-17;1-12(2)25-15-7-4-6-14(11-15)21-20(24)16-8-5-9-17-19(16)26-13(3)10-18(23)22-17;1-10-8-15(24)19-14-7-3-6-13(16(14)18-10)11-4-2-5-12(9-11)17-20-22-23-21-17/h5-6,8-12,26H,3-4,7H2,1-2H3,(H,27,30);4,7-9,11,13-14,23H,5-6,10H2,1-3H3,(H,24,27);5-6,8-12,23H,3-4,7H2,1-2H3,(H,24,27);2-7,9-12H,8H2,1H3,(H,22,25)(H,23,24);4-9,11-13H,10H2,1-3H3,(H,21,24)(H,22,23);2-7,9-10,18H,8H2,1H3,(H,19,24)(H,20,21,22,23)/t11-;13-;11-;12-;13-;10-/m111111/s1
InChIKeyLCHNGABGYQCIAH-IWHLHPASSA-N
MW2177.45 g/mol
LogP24.46
Rot. Bonds15

About (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one

(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one (PubChem CID 159309082) has the molecular formula C122H121F4N23O12 and a molecular weight of 2177.45 g/mol. Its IUPAC name is (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one.

Molecular Properties

Compound Name(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one
PubChem CID159309082
Molecular FormulaC122H121F4N23O12
Molecular Weight2177.45 g/mol
Exact Mass2175.95
IUPAC Name(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one
SMILESCC(C)Oc1cccc(NC(=O)c2cccc3c2O[C@H](C)CC(=O)N3)c1.C[C@@H]1CC(=O)Nc2cc(C(F)(F)F)cc(-c3ccc4c(c3)c(C3CC3)nn4C)c2N1.C[C@@H]1CC(=O)Nc2cc(F)cc(-c3ccc4c(c3)c(C3CC3)nn4C)c2N1.C[C@@H]1CC(=O)Nc2cccc(-c3cccc(-c4nn[nH]n4)c3)c2N1.C[C@@H]1CC(=O)Nc2cccc(C(=O)Nc3cccc(-c4cnco4)c3)c2O1.Cc1ccc(-c2ccc3c(c2)c(C2CC2)nn3C)c2c1NC(=O)C[C@@H](C)N2
InChIInChI=1S/C22H21F3N4O.C22H24N4O.C21H21FN4O.C20H17N3O4.C20H22N2O4.C17H16N6O/c1-11-7-19(30)27-17-10-14(22(23,24)25)9-15(21(17)26-11)13-5-6-18-16(8-13)20(12-3-4-12)28-29(18)2;1-12-4-8-16(22-20(12)24-19(27)10-13(2)23-22)15-7-9-18-17(11-15)21(14-5-6-14)25-26(18)3;1-11-7-19(27)24-17-10-14(22)9-15(21(17)23-11)13-5-6-18-16(8-13)20(12-3-4-12)25-26(18)2;1-12-8-18(24)23-16-7-3-6-15(19(16)27-12)20(25)22-14-5-2-4-13(9-14)17-10-21-11-26-17;1-12(2)25-15-7-4-6-14(11-15)21-20(24)16-8-5-9-17-19(16)26-13(3)10-18(23)22-17;1-10-8-15(24)19-14-7-3-6-13(16(14)18-10)11-4-2-5-12(9-11)17-20-22-23-21-17/h5-6,8-12,26H,3-4,7H2,1-2H3,(H,27,30);4,7-9,11,13-14,23H,5-6,10H2,1-3H3,(H,24,27);5-6,8-12,23H,3-4,7H2,1-2H3,(H,24,27);2-7,9-12H,8H2,1H3,(H,22,25)(H,23,24);4-9,11-13H,10H2,1-3H3,(H,21,24)(H,22,23);2-7,9-10,18H,8H2,1H3,(H,19,24)(H,20,21,22,23)/t11-;13-;11-;12-;13-;10-/m111111/s1
InChIKeyLCHNGABGYQCIAH-IWHLHPASSA-N
XLogP24.46
TPSA442.56 Ų
H-Bond Donors13
H-Bond Acceptors26
Rotatable Bonds15
Heavy Atoms161
Complexity—

Lipinski Rule of Five

4 violations

RuleValue
MW ≤ 5002177.45
LogP ≤ 524.46
H-Bond Donors ≤ 513
H-Bond Acceptors ≤ 1026

Analyze (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Frequently Asked Questions

What is the IUPAC name of (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one?
The IUPAC name of (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one (CID 159309082) is (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one.
What is the SMILES notation for (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one?
The canonical SMILES for (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one is CC(C)Oc1cccc(NC(=O)c2cccc3c2O[C@H](C)CC(=O)N3)c1.C[C@@H]1CC(=O)Nc2cc(C(F)(F)F)cc(-c3ccc4c(c3)c(C3CC3)nn4C)c2N1.C[C@@H]1CC(=O)Nc2cc(F)cc(-c3ccc4c(c3)c(C3CC3)nn4C)c2N1.C[C@@H]1CC(=O)Nc2cccc(-c3cccc(-c4nn[nH]n4)c3)c2N1.C[C@@H]1CC(=O)Nc2cccc(C(=O)Nc3cccc(-c4cnco4)c3)c2O1.Cc1ccc(-c2ccc3c(c2)c(C2CC2)nn3C)c2c1NC(=O)C[C@@H](C)N2.
What is the InChIKey of (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one?
The InChIKey is LCHNGABGYQCIAH-IWHLHPASSA-N. The full InChI is InChI=1S/C22H21F3N4O.C22H24N4O.C21H21FN4O.C20H17N3O4.C20H22N2O4.C17H16N6O/c1-11-7-19(30)27-17-10-14(22(23,24)25)9-15(21(17)26-11)13-5-6-18-16(8-13)20(12-3-4-12)28-29(18)2;1-12-4-8-16(22-20(12)24-19(27)10-13(2)23-22)15-7-9-18-17(11-15)21(14-5-6-14)25-26(18)3;1-11-7-19(27)24-17-10-14(22)9-15(21(17)23-11)13-5-6-18-16(8-13)20(12-3-4-12)25-26(18)2;1-12-8-18(24)23-16-7-3-6-15(19(16)27-12)20(25)22-14-5-2-4-13(9-14)17-10-21-11-26-17;1-12(2)25-15-7-4-6-14(11-15)21-20(24)16-8-5-9-17-19(16)26-13(3)10-18(23)22-17;1-10-8-15(24)19-14-7-3-6-13(16(14)18-10)11-4-2-5-12(9-11)17-20-22-23-21-17/h5-6,8-12,26H,3-4,7H2,1-2H3,(H,27,30);4,7-9,11,13-14,23H,5-6,10H2,1-3H3,(H,24,27);5-6,8-12,23H,3-4,7H2,1-2H3,(H,24,27);2-7,9-12H,8H2,1H3,(H,22,25)(H,23,24);4-9,11-13H,10H2,1-3H3,(H,21,24)(H,22,23);2-7,9-10,18H,8H2,1H3,(H,19,24)(H,20,21,22,23)/t11-;13-;11-;12-;13-;10-/m111111/s1.
What are the key properties of (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one?
(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one has a molecular weight of 2177.45 g/mol, XLogP of 24.46, 15 rotatable bonds, 13 hydrogen bond donors, and 26 hydrogen bond acceptors.
Where does this data come from?
All data for (4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4,9-dimethyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-8-fluoro-4-methyl-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(4R)-6-(3-cyclopropyl-1-methylindazol-5-yl)-4-methyl-8-(trifluoromethyl)-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one;(2R)-2-methyl-N-[3-(1,3-oxazol-5-yl)phenyl]-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(2R)-2-methyl-4-oxo-N-(3-propan-2-yloxyphenyl)-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide;(4R)-4-methyl-6-[3-(2H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-1,5-benzodiazepin-2-one is sourced from PubChem (CID 159309082), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).